Targeted therapy for pelvic pain associated with endometriosis. Assessment of quality of life and sexual function
article
OA: closed
CC0
⤵ 1 in-corpus citation
⚙
AI-generated summary
by claude@2026-06, 2026-06-08
ⓘ
Dienogest 2 mg daily administration in women with endometriosis-associated pelvic pain significantly reduced pain, improved quality of life, and enhanced sexual function over six months.
⚙
AI-generated deep summary
by claude@2026-06, 2026-06-09
ⓘ
This study assessed the efficacy of dienogest 2 mg once daily for female patients with confirmed genital endometriosis presenting with pelvic pain, focusing on quality of life and sexual function. Fifty-four patients were followed at 3 and 6 months using visual analogue scales for pelvic pain, dysmenorrhea, and dyspareunia, along with SF-36, FSFI, and FSDS measures, and compared against a group of 38 patients receiving NSAIDs; the study notes that all participants refused proposed surgical treatment. Dienogest showed a progressive reduction in pain intensity and significant improvements in quality-of-life categories by 6 months, with FSFI and FSDS improving between 3 and 6 months, while no changes were reported in the comparison group. This paper is centrally about endometriosis — it evaluates dienogest treatment for endometriosis-associated pelvic pain with outcomes including quality of life and sexual function.
Abstract
Objective. To study the efficacy of dienogest 2 mg in the treatment of female patients with pelvic pain associated with endometriosis in terms of improving the quality of life and sexual function. Patients and methods. The study group included 54 female patients with confirmed diagnosis of genital endometriosis (adenomyosis, infiltrating endometriosis, ovarian endometrial cysts). Dienogest 2 mg once daily was prescribed to all patients; 38 patients received non-steroidal anti-inflammatory drugs and constituted the comparison group. The visual analogue scale was used to assess pelvic pain, dysmenorrhea, and dyspareunia in patients with endometriosis. The 36-Item Short Form Survey (SF-36), the Female Sexual Function Index (FSFI), and the Female Sexual Distress Scale (FSDS) were used to assess the quality of life, sexual function, and sexual distress, respectively. The study contained two consecutive follow-ups after 3 and 6 months. All patients included in the study refused the proposed surgical treatment. Results. A slight decrease in chronic pelvic pain, dysmenorrhea, and dyspareunia was observed in the study group after 3 months (p < 0.05) with a progressive decrease in pain intensity by 6 months of dienogest administration (p < 0.001). The qualityof-life assessment showed a similar tendency: improvements were significant in several categories after 3 months (p < 0.05) and in all categories by 6 months (p < 0.001). The FSFI score had no changes after 3 months of follow-up (p with no statistical significance) but improved between 3 and 6 months (p < 0.001). The same was observed regarding the FSDS scale (p < 0.001). No changes were seen in the comparison group. Conclusion. Administration of dienogest 2 mg once daily in women with endometriosis-associated pelvic pain significantly reduces pain syndrome while positively affecting the quality of life and sexual function. Key words: dyspareunia, endometriosis, chronic pelvic pain, dienogest, quality of life, sexual activity
My notes (saved in your browser only)
Condition tags
endometriosisadenomyosischronic_pelvic_paindysmenorrheadyspareunia
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart;
here are the lists.
Cited by (1)
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK